Blog
RSS FeedPosted by Michael Wonder on 26 Apr 2024
Melphalan flufenamide hydrochloride in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
25 April 2024 - NICE is unable to make a recommendation on the use of melphalan flufenamide hydrochloride (Pepaxti) in combination ...
Posted by Michael Wonder on 25 Apr 2024
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment
24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young ...
Posted by Michael Wonder on 24 Apr 2024
Pembrolizumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced biliary tract cancer
24 April 2024 - NICE is unable to make a recommendation on the use of pembrolizumab (Keytruda) in combination with cisplatin ...
Posted by Michael Wonder on 23 Apr 2024
More treatment options proposed for people with multiple myeloma and myelodysplastic syndrome
23 April 2024 - PHARMAC is proposing to fund more treatments for people with a type of blood cancer, multiple ...
Posted by Michael Wonder on 22 Apr 2024
Boost for pharmacists for flu season
20 April 2024 - The Albanese Government is protecting Australians in aged care and disability homes by funding pharmacists for the ...
Posted by Michael Wonder on 19 Apr 2024
National pharmacare will reduce access to new medicines for 27 million privately insured Canadians
18 April 2024 - The federal Liberal-NDP coalition government recently announced it would work with the provinces to fund universal prescription ...
Posted by Michael Wonder on 19 Apr 2024
Publication of Stage 1 and Stage 2 PBS Process Improvements metrics report for 2022-23
19 April 2024 - The 2022-23 Stage 1 and Stage 2 PBS process improvements metrics report is now available on ...
Posted by Michael Wonder on 18 Apr 2024
PHARMAC's perpetually stretched budget
18 April 2024 - PHARMAC holds the keys to New Zealand's medicine cabinet, and what it dishes out is never enough. ...
Posted by Michael Wonder on 16 Apr 2024
DoH published revised agenda for July 2024 PBAC meeting (12 April 2024)
12 April 2024 - Version 2 of the agenda for the July 2024 PBAC meeting is now available; two minor ...
Posted by Michael Wonder on 15 Apr 2024
Updates to the HTA Policy and Methods Review Reference Committee (15 April 2024)
15 April 2024 - The HTA Review Reference Committee is finalising its report and recommendations to the Australian Government having ...
Posted by Michael Wonder on 14 Apr 2024
HTA review - is today D day?
15 April 2024 - The review is due to be completed by 15 April 2024 (today). ...
Posted by Michael Wonder on 12 Apr 2024
More treatments available to 30,000 New Zealanders
12 April 2024 - PHARMAC has decided to fund several medicines and widen access to two others, a move that will ...
Posted by Michael Wonder on 12 Apr 2024
Waiting for new medicines in Canada, Europe, and the United States: study finds Americans get better and faster access to innovative drugs
11 April 2024 - A recent study published by the Canadian Health Policy Institute examined the availability and wait times ...
Posted by Michael Wonder on 11 Apr 2024
NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld) for treatment of COVID-19
9 April 2024 - Final draft guidance for remdesivir and for tixagevimab with cilgavimab has been published by NICE. ...
Posted by Michael Wonder on 11 Apr 2024
170,000 people in England to have further treatment choice for preventing migraine attacks
11 April 2024 - In final draft guidance published today NICE has recommended atogepant, the first of a new type of ...